With the public availability of ChatGPT 3.5 in fall 2022 at the latest, artificial intelligence in the sense of large language models (L LMs) is on everyone’s lips. However, it is often forgotten that this is only the provisional end point of decades of development of artificial intelligence, which, despite its great potential, still has many limitations. The question for practising doctors is how this technology can be used sensibly in everyday clinical practice – and how it should not be used.
Autoren
- Dr. med. Lukas Dürst
- Dr. med. Marc Oertle
Publikation
- CARDIOVASC
Related Topics
You May Also Like
- Dermatoscopic findings of granulomatous diseases
Cutaneous sarcoidosis, necrobiosis lipoidica and granuloma anulare
- Clostridioides difficile infection: specific therapy
Importance of vancomycin and fidaxomicin has increased
- Study report
Asthma exacerbation risk in patients with a psychological comorbidity
- Neuropathies - CIDP
Differentiate chronic inflammatory demyelinating polyneuropathy (CIDP)
- Treatment of type 2 diabetes: paradigm shift continues
Cardiorenal organ protection is increasingly coming to the fore
- Semaglutide and tirzepatide in HFpEF and T2D/obesity
Prospect of improved cardiovascular prognosis
- Case report: alveolar sarcoidosis
Acute hypoxemic respiratory failure as initial manifestation
- "Swiss Health Care Atlas"